VolitionRX Limited Common Stock
Key Metrics
Market Snapshot
About
VolitionRX Limited Common Stock (VNRX) is a multi-national epigenetics company that develops blood tests to help detect and monitor a range of cancers and diseases associated with NETosis. The company is headquartered in Henderson, Nevada, and works across the United States, Europe, and Asia. It is known for its Nu.Q line of blood-based tests built on the analysis of nucleosomes.
The company's products are aimed at both animal and human health. Nu.Q Vet is a cancer screening test for dogs and other animals. Nu.Q Nets detects diseases associated with NETosis, such as sepsis. Nu.Q Discover is offered as a solution for profiling nucleosomes, supporting research and development work in the field.
For human cancer applications, the company provides Nu.Q Cancer, which is used for predicting treatment response, monitoring treatment response and disease progression, and helping adjust a patient's cancer treatment regimen. VolitionRx also offers Capture-PCR and Capture-Seq, which isolate and capture circulating tumor-derived DNA from plasma samples to support early cancer detection.
Together these products reflect a focus on epigenetics, the study of changes that affect how genes are expressed, applied to detecting and tracking disease through the blood. By covering veterinary screening, conditions linked to NETosis, research tools, and human cancer monitoring, VolitionRX Limited addresses several uses for its blood-based testing technology. Its activities center on developing and offering these diagnostic tests across the regions in which it operates, targeting clinical and research needs in cancer detection and in diseases connected to the NETosis process.